FDA approval vests Cardamyst PSUs for Milestone (MIST) Chief Commercial Officer
Rhea-AI Filing Summary
Milestone Pharmaceuticals Chief Commercial Officer Muller Lorenz reported multiple equity compensation events tied to regulatory and service milestones. On December 12, 2025, a performance stock unit award for 100,000 common shares vested after the U.S. Food and Drug Administration issued a New Drug Application Approval Letter for Cardamyst (etripamil), and a separate employee stock option for 100,000 shares with a $1.74 exercise price was granted, vesting in two halves on June 12, 2026 and December 12, 2026.
On January 26, 2026, 20,100 restricted stock units converted into common shares as part of an award that vests in four annual installments through January 26, 2029. Shares totaling 53,566 at a weighted average price of $2.32 and 11,180 at $1.93 were sold solely to cover tax liabilities from PSU and RSU vesting. After these transactions, Lorenz directly owned 205,406 common shares, 100,000 stock options, and 60,300 restricted stock units.
Positive
- FDA approval of Cardamyst (etripamil) is confirmed by the vesting trigger for 100,000 performance stock units, marking a major regulatory milestone for Milestone Pharmaceuticals.
- Equity incentives for the Chief Commercial Officer (PSUs, RSUs, and 100,000 stock options at a $1.74 exercise price) further align management compensation with Cardamyst’s approval and ongoing service.
Negative
- None.
Insights
FDA approval of Cardamyst triggered significant equity vesting for Milestone’s CCO.
The filing shows that a performance stock unit award for 100,000 common shares vested when the U.S. Food and Drug Administration granted a New Drug Application Approval Letter for Cardamyst (etripamil). This ties management compensation directly to achieving a key regulatory milestone.
In addition, 100,000 employee stock options with a $1.74 exercise price were granted, vesting in two tranches on June 12, 2026 and December 12, 2026, contingent on continued service. Further RSU vesting and related sell-to-cover sales indicate routine tax-driven liquidity rather than discretionary selling.
From an incentive perspective, the combination of vested PSUs, remaining RSUs, and options concentrates Muller Lorenz’s exposure on Cardamyst’s commercialization and the company’s longer-term performance. Future company filings may provide additional detail on how FDA approval of Cardamyst influences revenue and profitability.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 20,100 | $0.00 | -- |
| Exercise | Common Shares | 20,100 | $0.00 | -- |
| Sale | Common Shares | 11,180 | $1.93 | $22K |
| Sale | Common Shares | 53,566 | $2.32 | $124K |
| Grant/Award | Employee Stock Option (right to buy) | 100,000 | $0.00 | -- |
| Grant/Award | Common Shares | 100,000 | $0.00 | -- |
Footnotes (1)
- Represents a performance stock unit ("PSU") award that vested upon the certification by the Compensation Committee of the Board of Directors of the Issuer that the U.S. Food and Drug Administration has provided a New Drug Application Approval Letter granting approval of Cardamyst (etripamil). Each PSU represents a contingent right to receive one common share. Represents shares sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of PSUs or restricted stock unit ("RSU") awards only, respectively. The price reported is a weighted average price. These shares were sold in multiple transactions. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Each RSU represents a contingent right to receive one common share. 50% of the option will vest on June 12, 2026 and 50% will vest on December 12, 2026, subject to the Reporting Person continuing to provide service through each such date. One-fourth (1/4th) of the shares subject to the RSU award vested or will vest on each of January 26, 2026, January 26, 2027, January 26, 2028 and January 26, 2029, subject to the Reporting Person continuing to provide service through each such date.
